GLENMEDE TRUST CO NA - JUNO THERAPEUTICS INC ownership

JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 0.51 and the average weighting 1.3%.

Quarter-by-quarter ownership
GLENMEDE TRUST CO NA ownership history of JUNO THERAPEUTICS INC
ValueSharesWeighting
Q1 2018$7,0000.0%1560.0%0.00%
Q4 2017$7,000
+16.7%
1560.0%0.00%
Q3 2017$6,000
+200.0%
156
+4.0%
0.00%
Q4 2016$2,000
-75.0%
150
-25.0%
0.00%
Q4 2015$8,0000.0%2000.0%0.00%
Q3 2015$8,000
-20.0%
2000.0%0.00%
Q2 2015$10,000
-16.7%
2000.0%0.00%
Q1 2015$12,000
+20.0%
2000.0%0.00%
Q4 2014$10,0002000.00%
Other shareholders
JUNO THERAPEUTICS INC shareholders Q1 2016
NameSharesValueWeighting ↓
Biomark Capital Management Co. LLC 2,168,601$65,080,00086.12%
Crestline Management, LP 17,348,799$520,637,00066.02%
Omega Fund Management, LLC 1,229,512$36,898,00028.17%
SIB LLC 100,000$3,001,0002.42%
Clarius Group, LLC 117,896$3,538,0001.65%
BB BIOTECH AG 1,405,000$42,164,0001.48%
Duquesne Family Office 493,000$14,795,0001.31%
First Washington CORP 65,320$1,960,0001.10%
PFM Health Sciences, LP 1,124,285$33,740,0000.99%
Partner Investment Management, L.P. 18,376$551,0000.82%
View complete list of JUNO THERAPEUTICS INC shareholders